

11 **1. Abstract**

12 Seasonal malaria chemoprevention (SMC) has proven highly efficacious in reducing malaria incidence.
13 However, the continued success of SMC is threatened by the spread of resistance against one of its main
14 preventive ingredients, Sulfadoxine-Pyrimethamine(SP), operational challenges in delivery, and
15 incomplete adherence to the regimens. Via a simulation study with an individual-based model of malaria
16 dynamics, we provide quantitative evidence to assess long-acting injectables (LAIs) as potential alternatives
17 to SMC. We explored the predicted impact of a range of novel preventive LAIs as a seasonal prevention
18 tool in children aged three months to five years old during late-stage clinical trials and at implementation.
19 LAIs were co-administered with a blood-stage clearing drug once at the beginning of the transmission
20 season. We found the establishment of non-inferiority of LAIs to standard 3 or 4 rounds of SMC with SP-
21 amodiaquine was challenging in clinical trial stages due to high intervention deployment coverage.
22 However, our analysis of implementation settings where the achievable SMC coverage was much lower,
23 LAIs with fewer visits per season are potential suitable replacements to SMC. Suitability as a replacement
24 with higher impact is possible if the duration of protection of LAIs covered the duration of the transmission
25 season. Furthermore, optimizing LAIs coverage and protective efficacy half-life via simulation analysis in
26 settings with an SMC coverage of 60% revealed important trade-offs between protective efficacy decay
27 and deployment coverage. Our analysis additionally highlights that for seasonal deployment for LAIs, it
28 will be necessary to investigate the protective efficacy decay as early as possible during clinical
29 development to ensure a well-informed candidate selection process.

30

31 2. Background

32 Children carry the majority of the global malaria burden, with an estimated 67% of all malaria-related
33 deaths (272 000 in 2019) occurring in those under 5 years of age¹. In addition to effective and timely
34 treatment, prevention through vector control or drug-based prophylaxis has proven to be an effective
35 approach, reducing incidence and mortality². Especially in seasonal malaria transmission settings, where
36 malaria transmission is linked to the rainy months, well-timed preventive malaria interventions that protect
37 from infection during the transmission months can ease a substantial amount of malaria burden¹. The WHO
38 has recommended seasonal malaria chemoprevention (SMC) with monthly Sulfadoxine-
39 Pyrimethamine+Amodiaquine (referred to as SMC-SP+AQ) for children aged between 3 months and 5
40 years during the malaria transmission season since 2012³. SP+AQ provides a two-stage effect: while AQ
41 clears existing blood-stage infections, the long clearance half-life of SP prevents new infections. The impact
42 of SMC in seasonal settings has been widely demonstrated, achieving a protective efficacy of roughly 80%
43 against clinical episodes in a trial in Burkina Faso⁴, a reduction in incidence by 60% in routine
44 implementation in Senegal (80% deployment coverage of all eligible children)⁵, and a reduction in the
45 proportion of positive tests by 44% in routine implementation in Mali⁶.

46 Despite its potential, poor adherence and the spread of drug resistance limit the effectiveness of SMC.
47 Additionally, the monthly delivery of SMC-SP+AQ (one day of SP and three days of AQ) throughout the
48 transmission season is relatively expensive, due to human resources and especially due to operational
49 constraints during the rainy season⁷. Consequently, in 2019, only 62% of children living in SMC-eligible
50 areas in the Sahel subregion received SMC¹. Throughout the transmission season, coverage subsequently
51 decreased by 6% in Guinea⁸ and 20% in Mali⁹. Investigation of the adherence to the 3x AQ regimen within
52 one treatment course in a clinical trial in Niger showed that only 20% of children received the full regimen
53¹⁰. Additionally, the spread of resistance markers against SP was reported with increasing SMC deployment
54^{11, 12}, impacting the eligibility of regions for SMC¹³ as well as the protective efficacy after implementation
55¹⁴.

56 The need for alternative prevention tools that simplify deployment and possess a reduced risk of resistance
57 is pressing. In the absence of an effective vaccine, long-acting injectables (LAIs) with an anti-infective
58 effect could provide an alternative seasonal prevention tool by simplifying the deployment and reducing
59 the risk of resistance through decreased selection pressure for SP resistance¹⁵. Current candidate LAIs
60 include small molecule drugs^{16,17} or monoclonal antibodies (mAbs)^{18,19} that target the sporozoite stage or
61 liver stage of the malaria parasite, thereby serving as anti-infectives. The successful development of a LAI
62 entails the definition of appropriate product profiles and use cases which are specified in Target Product
63 Profiles (TPPs). Precisely, these specifications include LAI efficacy and safety prerequisites as well as
64 delivery modalities¹⁵. TPPs are living documents and therefore continuously updated as new evidence for
65 product requirements becomes available.

66 To justify the implementation of LAIs under the use case of seasonal malaria prevention, non-inferiority to
67 the existing intervention of SMC-SP+AQ must be met⁴. For new tools with new modes of action and/or
68 deployment modalities, proving non-inferiority to the standard of care is a crucial step and is usually
69 established in non-inferiority clinical trials conducted at late stages of tool development. Currently, it is not
70 yet known what clinical studies will be required for LAIs. In absence of efficacy data on LAIs, it is at the
71 current stage impossible to obtain insights about the circumstances in which LAIs have the potential to be
72 non-inferior. *In silico* modelling and simulation approaches of malaria transmission and control, allow the

73 quantification of the impact of varying tool specifications in relation to varying operational and setting
74 constraints which would not be feasible in real life clinical trials. They thus allow for the exploration of the
75 potential to meet non-inferiority criteria. In the absence of non-inferiority evidence at the early stages of
76 development, modelling and simulation approaches therefore provide a quantitative basis to further inform
77 decision making. They guide tool development from the early stages by predicting potential public health
78 impact (Fig. 1a)²⁰ and understanding non-inferiority criteria prior to clinical trial planning.

79 Here, we investigate the potential public-health impact for various use cases of LAIs by conducting an *in*
80 *silico* simulation analysis examining product properties and operational modalities supporting LAI
81 implementation as a seasonal malaria prevention tool. Accordingly, in the simulated scenarios, LAIs were
82 delivered to children under five once at the beginning of the transmission season with an antimalarial in
83 settings currently approved for SMC deployment. Their protective effect was then compared to SMC-
84 SP+AQ administered three or four times per season in monthly intervals. By combining disease modelling
85 and simulation experiments with machine learning approaches, we efficiently explored the large space of
86 possible parameter values describing intervention and transmission setting characteristics and analyzed
87 trade-offs between tool characteristics and operational constraints in a variety of transmission settings²⁰.
88 We conducted our malaria transmission simulations using *OpenMalaria*, an established individual-based
89 stochastic simulation platform of malaria transmission and control^{21 22}. Based on this approach, we defined
90 a quantitative framework to assess the influence of tool properties and operational constraints on the impact
91 of SMC and LAIs. Using this framework, we investigated two malaria transmission settings based on the
92 malaria transmission profile in Senegal and Mali and assessed public health impact for a plethora of
93 different tool properties, deployment coverages and over multiple transmission intensities. Our analysis
94 was carried out along the clinical development pathway from late clinical trials through to implementation
95 of future LAIs as an SMC replacement. By understanding the main drivers of impact to reach a pre-defined
96 health goal in implementation stages and under operational constraints, we provide an assessment of
97 endpoints in clinical trials of newly developed LAIs and identify efficacy requirements for further
98 development.

99 **3. Materials and Methods**

100 The impact of novel anti-infective LAIs depends on the tool properties defining their efficacy profile, as
101 well as on the operational constraints and the respective underlying malaria epidemiology, that influence
102 tool suitability for implementation in a given setting (Fig. 1a). We investigated the influence of tool
103 properties over a large range of specified protective efficacies, as well as operational considerations
104 (coverage of children) in several implementation settings varying in seasonality and access to healthcare.
105 The drivers of predicted impact for preventive LAIs were analysed along their clinical development from
106 clinical trials to implementation (Fig. 1b) and compared to current standard of care (SMC-SP+AQ).
107 Accordingly, we defined two analysis stages: in the *clinical trial stage*, we investigated the maximum
108 incidence reduction and the ability to establish non-inferiority to SMC-SP+AQ over one malaria season
109 (Fig. 1 b, panel 1). In the *implementation stage*, we replaced SMC-SP+AQ with LAIs after five years of
110 implementation at varying coverages, and we inferred the minimal LAI coverage at which LAIs are
111 equivalent (non-inferiority) in public-health impact (incidence reduction) to a continued implementation of
112 SMC-SP+AQ (Fig. 1b, panel 2).

113 We adapted a previously developed framework to inform TPPs of new interventions against infectious
114 diseases²⁰. First, a set of simulated scenarios was defined. These were characterized by the delivery

115 modality, tool specifications, and settings in which a concrete health target was analysed (in our case,
116 incidence reduction). Second, a set of disease scenarios were simulated randomly over the entire parameter
117 space to evaluate the health outcomes. The resulting database of simulations was used to train a Gaussian
118 process emulator (GP), that predicts the health outcome given a set of input parameters. Third, the emulator
119 was employed to perform sensitivity analysis and optimisation of tool properties with respect to health
120 outcomes. This analysis allowed us to define the optimal product characteristics of a LAI that maximises
121 the chance of achieving a desired health goal.

122 **Malaria disease transmission model**

123 We explored the dynamics of a preventive LAI against malaria using *OpenMalaria*, a stochastic, individual-
124 based simulator of malaria infection in humans linked to a deterministic model of the mosquito feeding
125 cycle^{23,24}. *OpenMalaria* accounts for heterogeneity within a human population on multiple levels including
126 host exposure, susceptibility and immune response^{21,25,26}. The model allows the investigation of
127 interventions against malaria at multiple points in the malaria life cycle (e.g. vaccines²², insecticide treated
128 bed-nets, and reactive case detection²⁷) while monitoring a variety of health outcomes (e.g. prevalence,
129 incidence, mortality)²⁸.

130 **Simulated disease scenarios**

131 Using *OpenMalaria*, we simulated a range of transmission settings (Fig. S1) and assumptions for the
132 implementation of SMC and LAIs as a seasonal infection prevention intervention replacing existing
133 prevention with SMC-SP+AQ. These assumptions are with regards to the properties of the setting
134 (seasonality and intensity of transmission), health system (access to care and treatment of clinical cases),
135 new and replacement intervention (Table 1).

136 The intervention age-group consisted of children between 3 months and 5 years of age (accounting for ca.
137 16% of the total population). The intervention age-group was chosen according to WHO recommendations
138³, although some countries have implemented SMC for children up to 10 years old²⁹. We assumed a total
139 population of 10,000 individuals to capture transmission settings within health facility catchment areas with
140 an age-structure that represents a realistic age-distribution for African malaria-endemic settings³⁰. Access
141 to treatment, defined as the percentage of the whole population who seek care for a symptomatic malaria
142 episode, was chosen to represent settings with low or high health systems strength. The probability of
143 symptomatic cases to receive effective treatment within two weeks from the onset of symptoms (E_{14}) was
144 set to 10% in low access to health-care settings and 50% in high access to health-care settings³¹. The
145 malaria seasonality profile, mosquito species and timing of interventions were parameterised to reflect those
146 of Mali or Senegal, two countries in the Sahel region where SMC is implemented and clinical trials for
147 malaria interventions are conducted frequently. In Mali, the malaria season is longer, starting in August and
148 lasting until November (*long season*), and SMC is generally four monthly doses. In contrast, the malaria
149 season in Senegal is only three months long, with a sharper profile (*short season*) and SMC is three doses
150 one month apart (Fig. 1a, Table 1, Figure S2). Malaria prevalence in Senegal is generally low, with the
151 highest *P. falciparum* prevalence in 2-10 years old (PfPR_{2-10y}) in the southern regions being around 8%.
152 However, the PfPR_{2-10y} in Mali is around 80% in the south of Mali but very low in the North³².

153 To develop a broader understanding of the influence of transmission intensity on LAI impact, we simulated
154 a range of initial incidence settings capturing the transmission heterogeneity of these two malaria-endemic

155 countries (Figure S1, Table S1). The simulated transmission intensity of each setting was defined by the
156 entomological inoculation rate (EIR) modelled as the average annual number of infectious bites received
157 by an individual, and the corresponding simulated PfPR_{2-10y} (Table S1, Fig. S1). The protective efficacy of
158 SMC-SP+AQ was implemented as being fully effective (no prevalent resistance against SP) or reduced
159 duration of protection (prevalent resistance against SP).

160 Over all simulation experiments, the input parameter space for the protective efficacy and its decay, and
161 the intervention coverage are as defined in Table 1. Parameters were randomly sampled using Latin
162 hypercube sampling³³ by drawing 1500 parameter sets for each setting, with 5 stochastic realizations
163 (simulation replicates) for each point. All simulations were performed using *OpenMalaria* version 38. The
164 source code and comprehensive documentation for *OpenMalaria*, including a detailed model of
165 demography, transmission dynamics and interventions is available at³⁴.

166 **Delivery: clinical trial and implementation assumptions**

167 In our study, LAIs were implemented as anti-infective entities in the form of mAbs or small molecule drugs,
168 that prevent the development of blood-stage malaria through action on malaria parasites in sporozoite or
169 liver stages. We assumed administration once at the beginning of the transmission season in combination
170 with an artemisinin combination therapy that cures prevalent blood-stage malaria infections with a 100%
171 cure rate. SMC-SP+AQ was administered monthly: three times per season in Senegal like settings (*short*
172 *season*) and four times per season in Mali like settings (*long season*) as recommended by the WHO³ (Fig.
173 S2). We assume a decrease in SMC coverage by 3% between treatments (ca. 10% over a four-doses
174 treatment regimen), therefore lying between the two extremes of observed coverage decrease^{8,9}.

175 The *clinical trial stage* (Fig. 1b, panel 1) was simulated in the high case management setting to account for
176 awareness of malaria symptoms. Initial deployment coverage levels for both, SMC and LAI, were set to
177 100%. Follow up visits, in the form of active case detection, were implemented two weeks after every
178 administration round of SMC-SP+AQ in both trial arm. In addition to fully effective SMC-SP+AQ, we
179 investigated a reduced length of protection by prevalent resistance against SP in the *clinical trial stage*.

180 In the *implementation stages* (Fig. 1b, panel 2), we analysed the impact of switching seasonal malaria
181 prevention strategies from SMC-SP+AQ after five years of implementation to LAIs. After five years of
182 LAI implementation, the cumulative clinical case incidence was compared to a control setting (no
183 switching). LAIs and SMC-SP+AQ were implemented with varying coverages between 40-100%.
184 Intervention cohorts, defined by the coverage in the intervention age group, were specified at the beginning
185 of a transmission season for the whole season. An exemplary illustration of LAI and SMC-SP+AQ
186 implementation is provided in Fig. S4.

187 **Intervention characteristics: SMC and LAI properties**

188 As the decay of efficacy of LAIs is not yet known, we explored a range of possible scenarios. In both the
189 clinical and implementation analysis, the prevention of infection by LAI was modelled as pre-erythrocytic
190 protection from infection $E(t)$ over time defined by the initial protective efficacy E_0 [%], protective efficacy
191 half-life of decay L and shape parameter k (Fig. S3). The decay shapes of protective efficacy were chosen
192 such that they represent multiple development possibilities: exponential-like decay (referred to as
193 *exponential LAIs*), malaria vaccine-like decay, namely biphasic-like decay^{35,36} (referred to as *bi-phasic*

194 LAIs) and sigmoidal-like decay (referred to as *sigmoidal LAIs*). The protective efficacy decay over time
 195 $E(t)$ for exponential and bi-phasic LAIs was modelled as either Weibull-like decay:

$$196 \quad E(t) = E_0 e^{-\left(\frac{t}{T}\right)^k \log(2)}, \quad \text{Eq. 1}$$

197 where $k=1$ yields *exponential LAIs* and $k=0.69$ yields *bi-phasic LAIs*. *Sigmoidal LAIs* were defined by the
 198 following Hill equation with $k=8$.

$$199 \quad E(t) = E_0 \frac{1}{1 + \left(\frac{t}{T}\right)^k}. \quad \text{Eq. 2}$$

200 The individual protection profile over time after one administration of SMC-SP+AQ, was parameterized
 201 using published clinical trial results⁴. The protection profile in preventing infections is not well understood
 202³⁷, and usually the protective efficacy of SMC-SP+AQ was assessed in clinical studies in terms of
 203 population survival estimates, risk reductions or a reduction in incidence^{9,38}. To compare the impact of
 204 novel LAIs with SMC-SP+AQ, we parameterized the protective efficacy of SMC-SP+AQ to data from a
 205 clinical non-inferiority trial conducted in Burkina Faso⁴. Our parameterization approach employs a
 206 Gaussian process regression model³⁹ to determine the model parameters that reproduce the clinical trial
 207 data via minimization of the residual sum of squares between the observed and simulated SMC-SP+AQ
 208 protective efficacy. A detailed description of the parameterization process is given in the Supplementary
 209 Information. Scenarios assuming SP resistance, the effect of resistance against the SMC component SP was
 210 implemented by decreasing the SMC half-life of protection from 32 days to 20 days. The lower protection
 211 half-life due to resistance can be modeled as an increase in the drug concentration inhibiting the parasite
 212 growth by 50% (IC_{50}). Because SP has a long clearance half-life⁴⁰, we assume no impact of resistance on
 213 the initial efficacy.

214 **Health target: endpoints to assess impact of LAI**

215 The health targets analysed in this study were based on incidence reduction by LAIs, clinical cases averted
 216 by LAIs compared to SMC, and non-inferiority with regard to clinical burden in the modelled clinical trials.
 217 Clinical cases per person in the intervention age group ($cpp_{0.25-5y, int}$) over the clinical trial length (Fig. 1a)
 218 ($cpp_{0.25-5y, int}$) or in the last implementation year ($cpp_{py0.25-5y, int}$) (Fig. 1b) were calculated over the whole
 219 population at risk in the intervention age-group ($N_{int, 0.25-5y}$).

$$220 \quad cpp_{0.25-5y, int} = \frac{\text{total cases}}{N_{0.25-5y, int}} \quad \text{Eq. 3}$$

221 The incidence reduction percentage inc_{red} was calculated via the cumulative incidence in the year before
 222 trial implementation cpp_{cont} and the cumulative incidence during the clinical trial cpp_{int}

$$223 \quad inc_{red} = \frac{cpp_{0.25-5y, cont} - cpp_{0.25-5y, int}}{cpp_{0.25-5y, cont}} \times 100 \quad \text{Eq. 4}$$

224 Survival analysis on the number of clinical cases per person cpp_{int} was performed to analyse the
 225 establishment of non-inferiority of LAIs to SMC-SP+AQ as described in⁴¹. The impact of a LAI is assumed
 226 to be non-inferior to SMC-SP+AQ if the upper limit of the derived 95% confidence interval of the hazard
 227 ratio between SMC-SP+AQ and LAI lies below the upper limit for non-inferiority. This limit is informed
 228 by the survival estimate of SMC-SP+AQ and the desired margin of non-inferiority. We assumed a margin

229 of non-inferiority of 5%. More information about the non-inferiority analysis is provided in the
230 Supplementary Information.

231 Additionally, the intervention impact defined as clinical incidence difference between SMC-SP+AQ
232 clinical cases per person per year $cpp_{0.25-5y, SMC}$ and LAIs $cpp_{0.25-5y, LAI}$ was compared using the relative
233 difference $diff_{cpp}$ as an indicator for the malaria burden.

234
235
$$diff_{cpp} = \frac{cpp_{0.25-5y, SMC} - cpp_{0.25-5y, LAI}}{cpp_{0.25-5y, SMC}} \quad \text{Equ. 5}$$

236 Gaussian process emulator approach to predict intervention impact

237 To perform a fast and efficient search of the parameter space of LAI properties, we used a database of
238 *OpenMalaria* simulations to train heteroskedastic GPs for each LAI efficacy decay type in each seasonal
239 and transmission intensity setting (R-package *hetGP*, function *mleHetGP*, Version 1.1.2.)⁴². The input
240 parameters of the GPs in the *clinical trial stage* consisted of the tool properties including initial protective
241 efficacy and protective efficacy half-life. In the *implementation stage*, the input parameters additionally
242 included the respective SMC-SP+AQ and LAI deployment coverage. To define the covariance structure of
243 the Gaussian process models, we used a Matérn kernel with smoothness parameter 5/2 accounting for the
244 high variability in the parameter space⁴². The trained GPs were then used to predict the number of cases
245 per person per year and the metrics related to the non-inferiority analysis (Table S2) for any point in the
246 parameter space. Emulator performance was ascertained by testing on a 20% holdout set after training on
247 80% of the data²⁰ (Table S2).

248 Sensitivity analysis

249 We identified the main drivers of intervention impact via a global sensitivity analysis, performed using
250 decomposition of variance via Sobol analysis on the emulator output predictions. We conducted an EIR-
251 stratified sensitivity analysis to assess the potential change in drivers of impact over the whole transmission
252 range. Within the pre-defined parameter space, the total effect indices quantify the interactions between
253 individual parameter contributions to the emulator output variance⁴³. The total effect indices were
254 normalized to obtain the relative importance of each parameter through division by their sum. The total
255 effect indices were estimated with a Monte Carlo sampling approach using the function *soboljansen* in the
256 R-packages *sensitivity* (version 1.16.2) with 500 000 sampled points and 1000 bootstrap replicates.

257 Intervention properties and coverage optimisation

258 In the *clinical trial stage*, we discretized the space of the initial protective efficacy and protective efficacy
259 half-life of LAIs within the range of plausible values (Table 1), yielding a two-dimensional grid of
260 parameter value combinations. At each grid point, we used the GP emulators to estimate the upper limit of
261 the confidence interval of the hazard ratio between the survival estimates in the SMC and LAI arm and the
262 non-inferiority margin and check if non-inferiority could be established for the given combination of
263 parameter values (cf. Non-inferiority Analysis in Supplementary Material). The contours of the resulting
264 non-inferiority surface yielded the thresholds of the minimal initial protective efficacy and protective
265 efficacy half-life needed to establish non-inferiority across different transmission settings (Fig. 3).

266 In the *implementation stage*, we additionally determined the minimum required LAI coverage and half-life
267 at which non-inferiority to SMC-SP+AQ could be established. At each grid point, we conducted a

268 constrained optimization, translating the non-inferiority condition into an inequality constraint by requiring
269 the difference between the upper limit of the confidence interval and the non-inferiority margin to be
270 positive. The optimization was conducted using an augmented Lagrange method (*gosolnp*, R-package
271 *Rsolnp*, Version 1.16) with a minimum of 3 starting values and 200 simulations. To determine the benefits
272 of reallocation of resources from reduced visits within a season towards increasing deployment coverage,
273 we compared the number of cases per person per year in a simulation with SMC implemented at a given
274 coverage to the number of cases per person per year with LAI at a coverage that was 20% higher than the
275 optimal coverage.

276

277 4. Results

278 Decay shape and duration of protective efficacy influence LAI impact

279 We assessed the obtained malaria incidence reduction in the simulated scenarios of the *clinical trial stage*
280 at high deployment coverage (100%) and found that the decay shape of LAI protective efficacy and
281 protection half-life play an important role in achieving a targeted incidence reduction (Fig. 2) in each
282 simulated clinical trial scenario. Additionally, we identified the parameter space in which a certain
283 incidence reduction cannot be achieved following LAI deployment under different setting assumptions
284 (below each curve in Fig. 2).

285 In settings with a more extended transmission season (Fig. 2 b, d and f), a longer LAI half-life is required
286 to reach the same predicted impact compared to the shorter season settings (Fig. 2 a, c, and e). A steeper
287 initial decrease of initial protective efficacy (Fig. 1a and Fig. S3) led to lower estimated incidence reduction,
288 with *bi-phasic LAIs* exhibiting the lowest predicted impact (Fig. 2 c and d), followed by *exponential LAIs*
289 (Fig. 2 a and b). The predicted impact of *sigmoidal LAIs* was largely determined by their half-life compared
290 to initial protective efficacy: an initial decrease in protective efficacy would require only a marginal increase
291 of the half-life needed to reach the desired incident reduction (Fig. 2 e and f). In contrast to *exponential*
292 (Fig. 2 a and b) and *bi-phasic LAIs* (Fig. 2 c and d), where the force of infection increased the required
293 minimum half-life of protective efficacy, the required minimum half-life for *sigmoidal LAIs* was not
294 significantly increased by the force of transmission (Fig. 2 e and f). A longer malaria transmission season
295 (Fig. 2 b, d, and f) was predicted to increase the half-life requirements to reach a desired incidence reduction
296 for all LAIs. In these longer transmission season settings, a predicted incidence reduction of over 80% was
297 not possible for *exponential* and *bi-phasic LAIs*.

298 Fig. 2 shows the exemplary extraction of minimum essential efficacy properties for a LAI with a given half-
299 life. For example, if the half-life of protective efficacy of a LAI was assumed to be 150 days, we predicted
300 that an initial protective efficacy of 88%, 96%, and 76% was required for *exponential*, *bi-phasic* and
301 *sigmoidal LAIs*, respectively (Fig. 2 a, c and e) to reach a clinical incidence reduction of 60% (short malaria
302 transmission season, initial cases per person per year_{0.25-5y} of 2.8).

303 Establishing non-inferiority of LAIs to SMC-SP+AQ in clinical trials is difficult

304 In the SMC-SP+AQ arm of the simulated *clinical trial stages*, we found a predicted mean achievable
305 incidence reduction of approximately 90 % in Mali and Senegal-like seasonal settings (Table S 3). Our
306 non-inferiority analysis (Fig. 1b, panel 3) demonstrated that the predicted establishment of non-inferiority
307 of *sigmoidal LAIs* to SMC-SP+AQ under the assumption of 100% initial deployment coverage could only
308 be met with LAI efficacy over 90% in both seasonal settings and half-life over 62 days in Senegal-like
309 (short season) and 88 days in Mali-like (long season) seasonal transmission patterns (Fig. 3). In agreement
310 with the analysis of attainable incidence reduction (Fig. 2), the predicted establishment of non-inferiority
311 was more feasible in settings with a shorter transmission season and lower initial malaria incidence (Fig. 3
312 a). For settings with a lower initial incidence (between 0.5 and 1 initial cases per person per year_{0.25-5y}), the
313 parameter space where non-inferiority could be established varied more than in higher initial incidence
314 settings. If resistance against SP was prevalent, which we modelled as a shorter duration of protection
315 through a decrease in protective efficacy half-life to 20 days (from 32 days), *sigmoidal LAIs* were predicted
316 to be non-inferior in a wider range of tool property combinations (Fig. 3, c and d). Nevertheless, non-
317 inferiority could not be established in any setting for any parameterization of *exponential* and *bi-phasic*

318 LAIs under clinical trial coverage assumptions. We conclude that the efficacy decay profiles of LAIs play
319 an important role for reaching the defined incidence reduction goals and establishing non-inferiority to
320 SMC-SP+AQ.

321 **The influence of protective efficacy half-life changes over the parameter space**

322 Moving from clinical field trials towards *implementation stages*, where LAIs are administered as a
323 replacement for SMC-SP+AQ (Fig. 1 b, panel 2), we analyzed the influence of underlying LAI efficacy
324 properties and deployment coverage on resulting intervention impact and non-inferiority to SMC-SP+AQ.

325 Our sensitivity analysis via decomposition of variance (Fig. 4) indicate that the influence of half-life of
326 protective efficacy depends on the length of the transmission season in *implementation stages*. An increase
327 in initial efficacy (Fig. 4 d) and deployment coverage (Fig.4 e) resulted in a linear increase in predicted
328 impact. In contrast, the influence of the protective efficacy half-life changed over the parameter space (Fig.
329 4 a, b and c), with a much steeper influence for changes in lower half-life ranges. We found a change in the
330 main source of variance of the impact of *sigmoidal LAIs* with increasing protective efficacy half-life (shown
331 in Fig. 4 a and b for a half-life threshold of 90 days). For instance, if the LAI half-life was less than 90 days
332 (Fig. 4a), the protective efficacy half-life and deployment coverage shared almost equal proportions of
333 attributable variance, accounting for 38 % to 52% of variance while the initial protective efficacy
334 contributed between 7% to 19%, depending on transmission intensity. However, for half-lives greater than
335 90 days (Fig. 4 b) the importance of deployment coverage increased from 54% to 85% and importance of
336 the initial protective efficacy from 14% to 38 % (in these results we assumed LAIs of less than 70% initial
337 protective efficacy are unlikely to be developed). In contrast, the relative importance of the protective
338 efficacy half-life decreased to around 2% to 12%. In settings with a longer malaria transmission season
339 (Fig. S6 a, d, g), a sharper initial decrease in clinical incidence was predicted for a larger range of protective
340 efficacy half-life than for shorter transmission seasons (Fig. S5 a, d, g). Overall, this demonstrates the
341 potential to explore how the impact determinants and their importance change based on efficacy duration
342 cut-offs compared to length of transmission season or alternative deployment.

343 **Trade-offs between enhancing duration of protection and implementation coverage**

344 These results illustrate the importance of setting-specific trade-offs between enhancing tool properties or
345 improving implementation coverage (Table 2). For example, increasing the half-life of a *sigmoidal LAI*
346 with an initial efficacy of 90% from 49 days to 63 days reduced the predicted required LAI coverage to
347 establish non-inferiority to SMC-SP+AQ in implementation (60 % coverage) by 20 % (from 100 % to 80
348 %) in a setting with an initial clinical incidence of 1.4 cases per person per year_{0.25-5y}. Furthermore, in
349 settings with relatively high levels of initial clinical malaria incidence and corresponding high transmission
350 intensity, namely cases per person per year_{0.25-5y}>2.4 and EIR>150, a change in dynamics to establish non-
351 inferiority was observed. In these settings, we predicted LAIs will likely fail to sufficiently protect the
352 targeted population from clinical malaria even at very high deployment coverage (Fig. S4). Therefore, we
353 were unable to assess the required half-life of protective efficacy of LAI for high transmission settings.

354 For SMC-SP+AQ, we estimated that an additional 13 % to 29 % in incidence reduction could be achieved
355 by increasing the coverage from 62% to 100%, dependent on initial clinical incidence before
356 implementation (Fig. S7). However, achieving high levels of SMC coverage at implementation is
357 challenging^{5,6}, and increasing levels of coverage are associated with increasing costs.

358 As information on costs of LAI (costs of goods and supply chain) are not available as of now, we were
359 unable to include detailed economic analysis in the assessment of LAIs in *implementation stages*. The main
360 cost drivers of SMC-SP+AQ are deployment costs (remuneration of health care workers) and cost of goods
361 ^{44,45}, with deployment costs increasing non-linearly with higher coverage. Therefore, we determined the
362 minimal LAI coverage at which non-inferiority to SMC-SP+AQ (assuming initial SMC deployment
363 coverage of 60%) was established, stratified by initial clinical incidence before implementation (Fig 5 and
364 Fig S8 and S9). We found that the parameter space where non-inferiority could be established shrank with
365 increasing baseline malaria incidence (Fig. S8 and S9). With regard to seasonality, LAIs were more likely
366 to be non-inferior in shorter malaria transmission settings in the *implementation stage* (Fig. S7 and Fig. S8).
367 In settings with a high initial clinical incidence (EIR=150, Table S1), LAI coverage could not be optimized
368 to be non-inferior to SMC-SP+AQ at 60% coverage because LAIs were unable to prevent malaria cases
369 even at very high coverage levels (Fig. S4d). Overall, the optimisation of LAI coverage in settings with a
370 limited SMC-SP+AQ coverage illustrates the potential of LAI implementation in non-optimal coverage
371 settings.

372 While non-inferiority could only be established in a small part of the parameter space of *sigmoidal LAIs* in
373 long seasonal transmission settings (Fig. 3b), it is possible to increase the potential area of applicability of
374 *sigmoidal LAIs* by optimising their deployment coverage (Fig. 5a, initial cases per person per year_{0.25-}
375 _{5y}=1.4). Deploying a sigmoidal LAI at 46% coverage with a half-life of 150 days and initial efficacy of
376 100% is sufficient to establish non-inferiority over SMC-SP+AQ at 60% coverage (Fig. 5 b). In contrast,
377 *sigmoidal LAIs* with a half-life of 70 days and initial efficacy of 70 % require a deployment coverage of
378 95% in order to be non-inferior (Fig. 5 e). For *sigmoidal LAIs* we found that increasing the deployment
379 coverage over the estimated minimum required coverage to establish non-inferiority results in potential
380 gains in terms of clinical incidence reduction compared to SMC-SP+AQ (Fig. 5 b to e).

381 Additionally, we found that even though non-inferiority of *exponential LAIs* to SMC-SP+AQ could not be
382 established in *clinical trial stages*, coverage optimisation in *implementation stages* reveals their
383 applicability. Deploying an *exponential LAI* at 52% coverage with a half-life of 150 days and initial efficacy
384 of 100% was sufficient to establish non-inferiority over SMC-SP+AQ at 60% coverage (Fig. S10b) and a
385 half-life of 100 days and initial protective efficacy of 90% requires a deployment of 78% to establish non-
386 inferiority (Fig. S10c). *Exponential LAIs* with a half-life of 70 days and initial efficacy of 70 % were always
387 inferior to SMC-SP+AQ at a coverage of 60% (Fig. S10e).

388 5. Discussion

389 The effective prevention of clinical malaria in children is crucial to prevent malaria mortality and reduce
390 the overall global malaria burden ¹. Through modelling and simulation, we explored a broad range of LAI
391 characteristics in multiple settings for clinical testing and deployment. This allowed us to understand the
392 likely influence of LAI efficacy properties and operational factors on clinical incidence reduction in
393 children under five years of age when LAI is deployed as a seasonal malaria prevention tool. We found that
394 if the protective efficacy of a new LAI decays immediately after injection, for example an exponential or
395 bi-phasic-like decay, then the LAI is unlikely to achieve non-inferiority over SMC-SP-AQ in current SMC
396 settings in a clinical trial. This exploration assumed non-inferiority criterion is required for testing, and we
397 only explored LAI half-life of protection in the range of 30 to 150 days. In contrast, when the protective
398 efficacy of LAIs is long-lasting and decays only after some time (i.e. a sigmoidal decay), there is a stronger
399 chance of achieving non-inferiority when the duration of protection is close to the transmission length.

400 Beyond clinical stages, by assessing implementation factors versus LAI properties, we conclude that
401 focusing on enhancing the duration of protective efficacy (half-life) is more likely to result in successful
402 LAIs in a larger range of incidence and transmission settings. If the half-life of protective efficacy of a LAI
403 approaches the length of transmission season, and initial efficacy is sufficiently high (depending on the
404 transmission intensity (Fig. 2)), then the development of new LAI should prioritize optimizing operational
405 delivery factors to ensure reasonable coverage to be as good as or better in averting clinical cases than
406 current SMC-SP+AQ implementation.

407 **The estimated impact of tool properties**

408 In general, the duration of the half-life and its shape of decay are the most relevant tool properties for
409 incidence reduction. This means that the development of new LAIs should focus on understanding the likely
410 decay and half-life of protection (this is not the pharmacokinetic properties of a small molecule or the
411 antibody longevity of a mAb). Over the analyzed transmission settings and parameter space, the estimated
412 minimum essential (80%) and ideal (95%) incidence reduction targets for LAIs as defined by Macintyre et
413 al. (2018)¹⁵ are hard to achieve in clinical testing. A desired incidence reduction of >80% in clinical testing
414 could only be achieved for LAIs with a sigmoidal decay shape and half-life over 60 days (Senegal, short
415 season) and 80 days (Mali, long season). Our findings indicate that key to identifying and refining
416 candidates for development of new LAIs is investigating the decay shape of efficacy as early as possible
417 and providing a sufficiently long protection half-life. Before conducting large scale clinical trials, it will
418 therefore be important to ensure the adequate means to establish the decay and duration of protection and
419 the ability to extrapolate to paediatric indications.

420 While the pharmacokinetic profile of potential LAIs can be evaluated in pharmacokinetic studies, their
421 protective efficacy profile and decay shape are harder to derive. Currently, murine⁴⁶ or human challenge
422^{47,48} studies are being used to investigate these parameters. In these studies, subjects receive treatment before
423 inoculation with sporozoites through the bites of infectious mosquitoes or direct venous injection^{47,48}.
424 However, parasite growth in the liver, and therefore protective efficacy, cannot be directly quantified.
425 Instead, the time and number of parasites entering the blood stream is used as a crude proxy for protective
426 efficacy. The approach presented here can aid to translate survival estimates from murine and human studies
427 by estimating the protective efficacy decay curves and then plugging them into the population modelling
428 approach with *OpenMalaria*. Hence, our approach can provide first insights into the potential public health
429 impact of new LAIs.

430 In summary, our findings suggest that when defining key efficacy characteristics in TPPs for LAIs there
431 are two important aspects to consider: i) evaluating the feasibility of currently or newly expect specified
432 LAI efficacy and duration requirements¹⁵ by estimating the likely public health impact of new LAIs with
433 e.g. modeling and simulation approaches, and by ii) translating population efficacy on clinical cases into
434 individual protection efficacy and vice versa via adequate summary measures of protective efficacy in
435 animal or human studies.

436 **Clinical non-inferiority trials**

437 Our non-inferiority analysis (Fig. 3) highlights that the establishment of non-inferiority in *clinical trial*
438 *stages* is challenging due to not only the high protective ability of SMC-SP+AQ but also clinical trial
439 designs. This motivates an important discussion on the clinical development of LAIs under the use-case of

440 SMC replacement: the necessity and extent of clinical trial testing or non-inferiority criteria should be
441 assessed. We estimated SMC-SP+AQ in a clinical study results in incidence reductions of 71% to 90% in
442 children under five, aligning to a efficacy of 86% (95% CI 78–91%) in a clinical trial in Senegal⁴⁹. Monthly
443 SMC-SP+AQ administration together with the estimated protective efficacy half-life of 32 days offers a
444 high degree of protection and the blood-stage clearing effect of AQ eliminates remnant malaria infections,
445 making optimally employed SMC a very powerful tool to prevent clinical malaria. This means it is difficult
446 for most LAIs to achieve non-inferiority in a clinical trial with limited SP resistance when the LAI is only
447 deployed once per season in combination with a blood stage clearing drug. Thus, at first glance, our non-
448 inferiority results may offer a distorted picture of the ability of LAIs to compete with current SMC, as
449 clinical non-inferiority trials do not reflect the reality of SMC implementation. Operational constraints
450 result in reduced coverage over the number of rounds^{5,6} and adherence¹⁰, thus hindering SMC with SP+AQ
451 from reaching its full potential. AS SMC-SP+AQ effectiveness reduces with operational challenges, this
452 presents a niche for LAIs. In 2019 only 62% of eligible children received SMC-SP+AQ¹, meaning that
453 additional incidence reduction could be achieved by increasing coverage at each round.

454 **Tool and coverage optimization in implementation stages**

455 Replacing SMC-SP+AQ with LAIs will likely prove beneficial in reducing deployment costs due to fewer
456 deployment rounds. In the absence of information on costs of LAIs (costs of goods and supply chain), we
457 are unable to adequately assess economic considerations and thus our results assume that coverage is the
458 main driver of implementation cost. If LAIs are assumed to have a longer clearance half-life and therefore
459 higher protective efficacy for longer than SP+AQ, resources are freed up through decreased deployment
460 rounds within a season. These resources could be reallocated to increase the overall coverage in a single
461 round of LAI in the target population, including populations in remote places. Additionally, the overall
462 adherence to the blood-stage clearing co-administration of antimalarials could be increased, thereby
463 reducing the probability of emergence of resistance. However, if transmission intensity is very high, we
464 found that the optimization of protective efficacy half-life and deployment coverage is insufficient to
465 adequately protect the targeted population. Instead, it might be necessary to expand the deployment of LAIs
466 to multiple administration rounds within a transmission season.

467 The optimization of deployment coverage of LAIs to reach non-inferiority to SMC-SP+AQ where optimal
468 coverage cannot be met exposes an additional use case for LAIs. If external circumstances, such as the
469 current COVID-19 pandemic, prevent the regular implementation of SMC and bed-nets campaigns,
470 millions of children will experience an increased risk of malaria⁵⁰, LAIs may alleviate this burden. Our
471 analysis can aid the identification of minimal LAI coverages necessary to achieve given population impacts
472 and prevent a resurgence in malaria cases.

473 **Framework and areas of application**

474 Our modelling and simulation analysis provides important insights into the likely impact of new malaria
475 tools that are currently under clinical development. Our modelling framework divides the unknown
476 parameter space of realistic properties of new tools into setting-specific attainable incidence reduction by
477 translating the decay of individual protection against infection of a new tool into estimates of population
478 impact on clinical incidence. While in clinical trials often only one (high) deployment coverage and a
479 limited number of trial-arms can be investigated, a simulation-based approach can explore the trade-off
480 between operational constraints and tool properties to narrow down beneficial implementation settings and

481 use cases without the need for expensive field studies. Not only does this approach offer the opportunity to
482 assess the potential population impact of new tools currently under development, but it also provides a
483 methodology to assess the potential clinical trial outcomes. It assists the evaluation of clinical trial scenarios
484 that might be considered over several different malaria transmission and health-system settings to
485 supporting thinking on appropriate population impact endpoints that are suitable to inform decision making.
486 This is particularly true for existing interventions with high efficacy for which the establishment of non-
487 inferiority in clinical non-inferiority trials is problematic, due to the required large sample sizes⁵¹. Here,
488 our approach offers first insights into the outcomes of such trials and the additional possibility to develop
489 clinical trial analysis tools.

490 Furthermore, beyond the current scope of our study, as more information on likely costs of LAIs become
491 available and further certainty in implementation and cold-chain needed, this work can serve as a basis for
492 cost-effectiveness or economic analysis.

493 As with all modelling studies there are limitations to our analysis. In this study, despite exploring a large
494 range of characteristics on tool properties, deployment, and transmission settings, our results are
495 constrained by the investigated parameter-space. First, we only investigated the impact of one
496 administration round of LAIs with an antimalarial treatment and assumed that the time-point of
497 administration would coincide with the first SMC application round. However, depending on the LAI
498 profile, the time of deployment may need to be optimized. Second, the implementation of protective
499 efficacy of LAIs is solely assumption-driven, as clinical data is not yet available. With additional
500 information on likely achievable protective efficacy half-life, initial protective efficacy and efficacy decay
501 shapes, the preliminary LAI profiles can be further defined and reevaluated as LAIs are developed. The re-
502 definition of plausible parameter ranges will also impact the results of the sensitivity analysis and trade-
503 offs, and potentially shift the recommended focus of development efforts. Additionally, target mediated
504 drug disposition might change the pharmacokinetic profile of mAbs dependent on the transmission intensity
505 and parasite growth within the human host and therefore also its efficacy profile⁵². Third, the focus of this
506 analysis was the investigation of the effect of the anti-infective LAIs. Our results are subject to change if
507 LAIs are co-administered with different blood-stage clearing drugs (different efficacies and/or potential
508 properties e.g. transmission blocking) or are deployed with other interventions such as insecticide-treated
509 bed-nets. And lastly, we explored SMC or LAI replacement in only children under 5 years of age and in
510 settings similar to where SMC is currently deployed such as Mali and Senegal. Further analysis could be
511 undertaken to assess LAI as seasonal prevention in children under 10 years of age, however we expect
512 conclusions to be similar in regards tool properties and coverage requirements. Our results also only hold
513 for assessing LAI as replacing SMC; we did not explore use cases of deploying LAI in perennial or other
514 settings in which SMC is not yet deployed. Alternative clinical metrics would need to be explored as LAI
515 in these use-cases are not a replacement tools, rather new tools and non-inferiority trials are not relevant.
516 Although this study focuses on the use of LAIs in seasonal malaria transmission settings, our findings
517 regarding the importance of protective efficacy half-life do provide first insights for potential use of a LAIs
518 in perennial malaria transmission settings. The protective efficacy half-life of a LAI will most likely dictate
519 the number of applications to children within one year to ensure effective clinical case reduction.

520 **Current stage of development of mABs and duration of protection**

521 Potential candidate LAIs include mABs and small-molecule drugs, and to date most known mABs for use
522 in malaria (largely by-products from research into whole sporozoite vaccines⁵³) have been shown to prevent
523 blood-stage infection in *in vitro* and/or *in vivo* murine malaria infection experiments^{18,19}. As the natural
524 clearance half-life of antibodies ranges between 2 and 21 days⁵⁴, strategies to increase the half-life of mABs
525 have been introduced via modifications to the tail (Fc) region of antibodies that interacts with the receptors
526 on the surface of cells. Fc-modified mABs have exhibited extended half-lives ranging from, 100 days⁵⁵ and
527 80 to 112 days⁵⁶ in healthy human adults. Our results suggest that these extended half-lives, if functional
528 malaria protection is maintained, are crucial to establish non-inferiority to standard SMC. A second stream
529 of LAI development is focused around small-molecule drugs such as atovaquone¹⁶ and P218¹⁷. Although
530 these compounds show promising liver-stage activity, the estimated clearance half-life of enhanced
531 formulation atovaquone of 32 days in humans¹⁶ and 8.9-19.6 hours of P218 in first-in-human trials⁵⁷ are
532 again likely insufficient in the use cases explored in our study and emphasize the need for longer-lasting
533 formulations to be useful as SMC replacements when deployed only once per season. Further use may be
534 possible for multiple applications within a season.

535 **Conclusion**

536 Here, we provided the first quantitative evaluation of the TPPs of future LAIs for malaria as a seasonal
537 prevention tool in children. Simulation analysis of LAIs in real-life implementation settings revealed that
538 the ability of LAIs to prevent clinical cases in children is strongly dependent on the length of the malaria
539 transmission season and transmission intensity. We also found it is important to focus on improving the
540 protective efficacy duration (half-life) of LAIs in development, as the speed of protective efficacy decay is
541 a key driver of overall impact or the chance to meet non-inferiority criteria compared to SMC-SP+AQ.
542 However, if a reasonable duration is possible (longer half-life and sigmoidal decay that supports protection
543 close to the length of transmission season) then development should focus on increasing deployment
544 coverage to optimizing the LAIs chance of higher impact. This provides evidence for the potential trade-
545 offs between tool properties and operational constraints as LAIs are developed and deployed. In general,
546 our findings support the need for a thorough and combined investigation of tool properties and use cases in
547 the future development of LAIs. This combined effort includes earlier modelling alongside clinical studies
548 to provide evidence of translation of impact at population levels before late stage clinical studies and
549 optimize the success of new malaria tools. Our research here provides an initial foundation to support
550 dialogue between stakeholders, scientists, and clinicians at each clinical development stage of novel anti-
551 infective LAI's to reduce clinical malaria incidence. LAIs have the potential to be a game changer in
552 protecting vulnerable populations from malaria. Our analysis serves as a stepping stone for the refinement
553 of TPPs for LAIs, thereby assisting the target-oriented use-case of development and implementation of new
554 LAIs.

555 **List of abbreviations**

SMC	Seasonal malaria chemoprevention
LAI	Long acting injectable
TPP	Target product profile
mAB	Monoclonal antibody
SP+AQ	Sulfadoxine-Pyrimethamine+Amodiaquine
GP	Gaussian process

556

557 **6. Declarations**

558 ***Ethics approval and consent to participate***

559 Not applicable

560 ***Consent for publication***

561 Not applicable

562 ***Competing interests***

563 J.J.M. is employed by the Medicines for Malaria Venture. All other authors declare no competing interests.

564 ***Funding***

565 The work was funded by the Swiss National Science Foundation through SNSF Professorship of MAP
566 (PP00P3_170702).

567 ***Authors' contributions***

568 LB, ML, MP, and MG designed the simulation experiments and the computational framework. LB and ML
569 carried out the simulations, analysis and visualisation. LB, ML, MG, TR, JJM, and MP contributed to the
570 interpretation of the results. LB wrote the manuscript with input from ML, MG, TR, JJ, and MP. MP and
571 LB conceived the study and were in charge of overall direction and planning. MP supervised the project.
572 All authors read and approved the final manuscript.

573 ***Acknowledgments***

574 We acknowledge and thank our colleagues in the Swiss TPH Infectious Disease Modeling unit for their
575 valuable insights and feedback. Calculations were performed at sciCORE (<http://scicore.unibas.ch/>)
576 scientific computing center at University of Basel.

577

578

579 **Tables and Figures**

580 **Table 1: Summary of simulation set-up used for the implementation experiments.** The simulated
 581 transmission settings were defined using a factorial design covering all possible combinations of discrete
 582 health system and vector specifications. The parameters defining the efficacy and delivery profiles of LAIs
 583 (highlighted in bold in the third column) were sampled within the defined parameter space using Latin
 584 Hypercube Sampling and simulated for each combination of settings. The effective coverage E_{14} describes
 585 the probability that effective malaria treatment will occur within a 14-day period since symptoms onset.
 586 Additional information on simulated transmission intensity can be found in the Supplement (Fig. S1 and
 587 Table S1).

	Parameter	Setting	Value							
Health system	Access to treatment (effective treatment coverage ⁵⁸ E_{14})	High access	0.5							
		Low access	0.1							
	Diagnostics	-	Rapid diagnostic test							
	Malaria treatment	-	First line: ACT Treatment failure/Severe malaria: Quinine							
Malaria transmission	EIR [infectious bites per person per year] and yearly cases per person per year [cppy _{0.25-5y}]	High access	EIR	5	9	20	47	150		
		Long season	cppy _{0.25-5y}	0.42	1	1.6	2.2	2.9		
		Short season	cppy _{0.25-5y}	0.49	0.95	1.52	2.04	2.83		
		Low access	EIR	3	4	8	28	150		
		Long season	cppy _{0.25-5y}	0.41	0.71	1.4	2.4	3.3		
		Short season	cppy _{0.25-5y}	0.45	0.72	1.3	2.3	3.2		
	Mosquito species	-	<i>An. gambiae</i>							
	Biting behavior		60% indoor biting, 40% outdoor biting							
	Seasonality in malaria transmission [% yearly EIR]	Senegal-like short season ⁵⁹		Jul	Aug	Sep	Oct	Nov	Dec	
		Mali-like long season ⁶⁰		0	20	60	20	0	0	
Interventions	Timing of interventions	Senegal-short season	3x SMC: Sep, Oct, and Nov							
		Mali-long season	4x SMC: Aug, Sep, Oct, and Nov							
	Intervention cohort		3mo. – 5 years							
	Population treated		Coverage: [40 - 100] %							
	Protective efficacy LAI			Initial efficacy: [70 - 100] %						
				Half-life: [30-150] days						
				Decay shape:						
		exponential LAIs		Exponential decay, $k=1$ (Eq. 1)						
	bi-phasic LAIs		Bi-phasic decay, $k=0.69$ (Eq. 1)							
	sigmoidal LAIs		Sigmoidal decay, $k=8$ (Eq. 2)							
Protective efficacy SMC-SP+AQ			Initial efficacy: 100 %							
			Half-life: 32 days							
			Decay shape: Weibull, $k=5.4$ (Eq. 1)							
			Adherence declining by 10% over the season							


588

589 **Table 2: Illustration of the trade-offs between LAI protective efficacy half-life, initial protective**
 590 **efficacy and coverage in implementation stages.** The table displays the estimated minimum half-life of
 591 LAI protective efficacy (measured in days, estimated values specified in the colored cells, increasing colour
 592 intensity illustrates increasing requirements) required to reach non-inferiority in implementation stages of
 593 various LAI profiles compared to SMC-SP+AQ deployed at 60% coverage for each of 3 or 4 rounds in a
 594 setting with low access to health care ($E_{14} = 0.1$). SMC-SP-AQ protective efficacy specifications are
 595 summarized in Table 1. Results are shown for different levels of LAI coverage, decay shapes (exponential
 596 or sigmoidal), initial protective efficacy and malaria incidence prior to deployment (initial cases per person
 597 per year_{0.25-5y}).

Efficacy [%]	initial cases per person per year _{0.25-5y}	Exponential LAIs Coverage [%]				Sigmoidal LAIs Coverage [%]			
		40%	60%	80%	100%	40%	60%	80%	100%
70%	0.41	-	-	113	62	-	-	85	59
	0.71	-	-	-	70	-	-	87	63
	1.4	-	-	-	89	-	-	103	63
	2.4	-	-	-	93	-	-	105	79
	3.3	-	-	-	-	-	-	-	-
80%	0.41	-	-	109	54	-	-	71	52
	0.71	-	-	112	62	-	148	74	55
	1.4	-	-	132	64	-	-	77	57
	2.4	-	-	119	75	-	-	84	62
	3.3	-	-	-	-	-	-	-	-
90%	0.41	-	-	81	48	-	102	61	50
	0.71	-	-	79	52	-	86	64	52
	1.4	-	-	90	56	-	103	63	49
	2.4	-	-	92	62	-	97	72	56
	3.3	-	-	-	-	-	-	-	-
100%	0.41	-	112	62	46	-	78	58	47
	0.71	-	115	69	48	-	78	58	49
	1.4	-	131	71	49	-	78	58	47
	2.4	-	119	72	52	-	80	61	47
	3.3	-	-	-	-	-	-	-	-

598


599



600

601 **Figure 1: Workflow to assess the target product profile of LAIs.** (a) In an iterative exchange between
 602 various stakeholders, definition of TPPs is informed by results from modelling approaches. Simulation of
 603 predefined scenarios with *OpenMalaria*, an individual based model of malaria dynamics, allows to estimate
 604 the impact (incidence reduction) of LAIs in the context of deployment setting details (access to healthcare
 605 and seasonality), deployment coverage of the target population and the tool properties (initial protective
 606 efficacy against infection, protective efficacy half-life and decay of protective efficacy). The resulting
 607 evaluation of LAI impact is communicated and discussed with stakeholders to refine the analysis as LAIs
 608 are developed. (b) The analysis in the clinical trial and implementation stage are illustrated on the example
 609 of two hypothetical LAIs with different efficacy profiles (denoted LAI 1 and 2). (1) In clinical trial stages,
 610 the minimum essential properties to reach a certain health goal are evaluated in a two-arm clinical trial .
 611 SMC-SP+AQ is administered (green arrows) three (as in Senegal, filled arrows) or four (as in Mali, filled
 612 and unfilled arrows) times over the transmission season. LAIs are administered once at the beginning of
 613 the transmission season (blue filled arrow for Senegal and blue empty arrow for Mali). The cumulative
 614 cases per person over the trial period are tracked. (2) In implementation stages, SMC-SP+AQ is replaced
 615 with LAIs after five years of implementation. Impact is assessed in the last implementation year (grey bar)
 616 and compared to the baseline of SMC-SP+AQ implementation. Coverages of SMC-SP+AQ and LAIs
 617 are independent from each other. (3) Upper panel: the tool properties influencing the establishment of non-
 618 inferiority of LAIs to SMC are investigated in the clinical trial stage. Lower panel: at a fixed SMC
 619 deployment coverage, the minimum coverage of LAI deployment required to establish non-inferiority is
 620 identified.


621



622

623 **Figure 2: Achieving targeted malaria incidence reduction depends on the decay shape of the LAIs**
 624 **protective efficacy.** Estimated relationships between initial protective efficacy and efficacy half-life for
 625 different incidence reduction criteria (40%, 60% and 80%, line style and color) and clinical incidence
 626 settings (increasing color intensity indicates an initial clinical incidence measured in cases per person per
 627 year in the target age group of 0.5, 1, 1.5, 2, and 2.8). Each line shows the minimum required LAI
 628 characteristics to reach the desired health goal at a 100% LAI deployment coverage at *clinical trial stage*,
 629 with all parameter combinations below a line failing to meet those requirements. The panels show
 630 the parameter space of attainable incidence reductions within the specified constrained ranges of initial
 631 protective efficacy and half-life for *exponential LAIs* (a, b), *bi-phasic LAIs* (c, d) and *sigmoidal LAIs* (e, f)
 632 in settings with a short (Senegal-like a, c, e) or long (Mali-like b, d, f) malaria season. The incidence
 633 reduction was calculated by comparing the incidence over one transmission season after application of the


634 LAI compared to the previous transmission season. The incidence reductions were obtained by predicting
 635 the cases per person per year_{0.25-5y} via our emulator approach (See Methods and Supplementary Information)
 636 in a fine grid defined over the parameter space (increments of 0.1 h for half-life and 0.01% for initial
 637 protective efficacy) and calculating the incidence reduction by comparison to the initial clinical incidence
 638 measured in cases per person per year_{0.25-5y} in the respective transmission intensity setting.



639


640 **Figure 3: Parameter space under which sigmoidal LAIs achieve non-inferiority compared to SMC-**
 641 **SP+AQ in the clinical trial stage.** We investigated the ability of *sigmoidal LAIs* to establish non-inferiority
 642 in clinical trials with an optimal deployment coverage (100%) in settings with a short (a, c) and long (b, d)
 643 malaria season and over varying initial malaria incidence (initial cases per person per year_{0.25-5y}). (a, b)
 644 SMC-SP+AQ has an initial protective efficacy of 100% and a half-life of 32 days parameterised from
 645 previous clinical trial data¹. The influence of prevalent SP-resistance (c, d) was analyzed by decreasing the
 646 protective efficacy half-life of SP from 32 days to 20 days (see Supplementary Information). The coloured
 647 area defines the limits of the parameter space where non-inferiority could be established through
 648 comparison of the difference hazard ratio δ between Kaplan-Meier survival estimates (see Supplementary
 649 information). The white area describes the parameter space where LAIs are inferior. *Sigmoidal LAIs* can
 650 achieve non-inferiority compared to SMC for lower durations of protection in a shorter malaria transmission
 651 season. *Exponential LAIs* and *bi-phasic LAIs* could not establish non-inferiority to SMC-SP+AQ.
 652

long season; sigmoidal LAIs



653

654 **Figure 4: Estimated importance of LAI properties and operational factors on the level of clinical**
 655 **incidence reduction.** Results are shown for the *implementation stage* for *sigmoidal LAIs* in a setting with
 656 low access to care and long malaria transmission season. **(a, b)** Sobol sensitivity analysis estimates the
 657 relative importance of LAI coverage, initial protective efficacy and half-life of protective efficacy to the
 658 variance of the emulator through decomposition of variance over the entire evaluated parameter space
 659 (coverage 40-100%, initial efficacy 70-100% and half-life **(a)** 30-90 days and **(b)** 90-150 days). Changes
 660 in clinical incidence measured as cases per person per year_{0,25-5y} with increasing tool properties or
 661 deployment coverage across the parameter space are shown for **(c)** half-life (30-150 days), **(d)** initial
 662 efficacy (80-100%) and **(e)** coverage (40 -100 %). The lines represent the mean and the 95%- confidence
 663 bands (shaded area) capture the distribution of incidence reduction across all sampled values. The dotted
 664 line in panel c indicates the split of half-life range for sensitivity analysis in panel a and b. Increasing color
 665 intensity represents increasing initial cases per person per year_{0,25-5y}. Further results for different decay
 666 shapes and length of transmission season are shown in the Supplementary Figures S4 and S5.



667

668 **Figure 5: Estimated minimal LAI coverage required during *implementation stages* to achieve non-**
 669 **inferiority in a given setting and predicted gains in cases averted of subsequent *sigmoidal* LAI**
 670 **coverage increments. (a) Heatmap of the estimated minimal coverage (colour) of *sigmoidal* LAIs at which**
 671 **non-inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60%) is achieved for different**
 672 **combinations of *sigmoidal* LAI efficacy and half-life. The results are displayed for intervention scenarios**
 673 **with an underlying disease burden of 1.4 cases per person per year_{0.25-5y}, long malaria transmission season**
 674 **and low access to treatment ($E_{14}=0.1$). In the grey area, non-inferiority of LAIs could not be established**
 675 **for any coverage. The light blue frames capture the tool characteristics where non-inferiority could be reached**
 676 **with a LAI coverage under the reference SMC-SP+AQ coverage of 60%. Further results for additional**
 677 **settings and decay shapes are provided in the supplement (Fig. S8 and S9). The coloured dots represent**
 678 **four illustrative LAI profiles for which the corresponding predicted relative differences in cases per person**
 679 **per year_{0.25-5y} (Eq. 5) are calculated in (b-e) five years after LAI introduction over all LAI coverages as**
 680 **compared to SMC-SP+AQ at 60% coverage (vertical dotted line). The predicted positive increase in relative**
 681 **difference in yearly clinical cases (above the dotted horizontal line) means more clinical cases are averted**
 682 **with LAIs than with SMC-SP+AQ. It thus illustrates the benefit of increasing *sigmoidal* LAI-coverage**
 683 **above the minimal required coverage to achieve non-inferiority (shown by the grey coloured area). Due to**
 684 **the chosen margin of non-inferiority (here 5%, see Material and Methods), LAIs are non-inferior for a slight**
 685 **negative relative difference in cases per person per year_{0.25-5y}. In the light-blue area in (b), a LAI coverage**
 686 **lower than the SMC-SP+AQ coverage is sufficient to establish non-inferiority. The corresponding analysis**
 687 **for *exponential* LAIs can be found in Fig. S10.**

688

- 689
- 690 1. WHO. *World malaria report 2019*. (World Health Organization, 2019).
- 691 2. Bhatt, S. *et al.* The effect of malaria control on *Plasmodium falciparum* in Africa between 2000
692 and 2015. *Nature* **526**, 207–211 (9).
- 693 3. WHO. *WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium*
694 *falciparum* *malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa*. (World
695 Health Organization, 2012).
- 696 4. Zongo, I. *et al.* Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared
697 with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina
698 Faso. *Antimicrob. Agents Chemother.* **59**, 4387–4396 (2015).
- 699 5. Cisse, B. *et al.* Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years
700 of Age in Senegal: A Stepped-Wedge Cluster-Randomised Trial. *PLoS Med* **13**, e1002175 (2016).
- 701 6. Druetz, T. Evaluation of direct and indirect effects of seasonal malaria chemoprevention in Mali.
702 *Sci. Rep.* **8**, 8104 (2018).
- 703 7. Coldiron, M. E., Von Seidlein, L. & Grais, R. F. Seasonal malaria chemoprevention: successes and
704 missed opportunities. *Malar. J.* **16**, 481 (2017).
- 705 8. Loua, K. & Milligan, P. *Seasonal Malaria Chemoprevention Coverage Survey in Guinea, 2018*.
706 (2019).
- 707 9. Diawara, F. *et al.* Measuring the impact of seasonal malaria chemoprevention as part of routine
708 malaria control in Kita, Mali. *Malar. J.* **16**, 325 (2017).
- 709 10. Ding, J. *et al.* Adherence and Population Pharmacokinetic Properties of Amodiaquine When Used
710 for Seasonal Malaria Chemoprevention in African Children. *Clin Pharmacol Ther* (2019)
711 doi:10.1002/cpt.1707.
- 712 11. Somé, A. F. *et al.* Selection of drug resistance-mediating *Plasmodium falciparum* genetic
713 polymorphisms by seasonal malaria chemoprevention in Burkina Faso. *Antimicrob. Agents Chemother.* **58**,
714 3660–3665 (2014).
- 715 12. Dieng *et al.* Contrasting Asymptomatic and Drug Resistance Gene Prevalence of *Plasmodium*
716 *falciparum* in Ghana: Implications on Seasonal Malaria Chemoprevention. *Genes* **10**, 538 (2019).
- 717 13. van Lenthe, M. *et al.* Markers of sulfadoxine–pyrimethamine resistance in Eastern Democratic
718 Republic of Congo; implications for malaria chemoprevention. *Malar. J.* **18**, 430 (2019).
- 719 14. WHO. *Seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in*
720 *children: A field guide*. (World Health Organization, 2013).
- 721 15. Macintyre, F. *et al.* Injectable anti-malarials revisited: discovery and development of new agents
722 to protect against malaria. *Malar. J.* **17**, 402–402 (2018).

- 723 16. Bakshi, R. P. *et al.* Long-acting injectable atovaquone nanomedicines for malaria prophylaxis. *Nat.*
724 *Commun.* **9**, 315 (2018).
- 725 17. Yuthavong, Y. *et al.* Malarial dihydrofolate reductase as a paradigm for drug development against
726 a resistance-compromised target. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 16823–16828 (2012).
- 727 18. Kisalu, N. K. *et al.* A human monoclonal antibody prevents malaria infection by targeting a new
728 site of vulnerability on the parasite. *Nat Med* **24**, 408–416 (2018).
- 729 19. Tan, J. *et al.* A public antibody lineage that potently inhibits malaria infection by dual binding to
730 the circumsporozoite protein. *Nat. Med.* **24**, 401–407 (2018).
- 731 20. Golumbeanu, M. *et al.* A quantitative approach to guide development of novel disease
732 interventions, submitted. (2020).
- 733 21. Maire, N. *et al.* A model for natural immunity to asexual blood stages of *Plasmodium falciparum*
734 malaria in endemic areas. *Am. J. Trop. Med. Hyg.* **75**, 19–31 (2006).
- 735 22. Penny, M. A. *et al.* Public health impact and cost-effectiveness of the RTS,S/AS01 malaria vaccine:
736 a systematic comparison of predictions from four mathematical models. *Lancet Lond. Engl.* **387**, 367–375
737 (2016).
- 738 23. Chitnis, N., Hardy, D. & Smith, T. A periodically-forced mathematical model for the seasonal
739 dynamics of malaria in mosquitoes. *Bull. Math. Biol.* **74**, 1098–1124 (2012).
- 740 24. Chitnis, N., Smith, T. & Steketee, R. A mathematical model for the dynamics of malaria in
741 mosquitoes feeding on a heterogeneous host population. *J. Biol. Dyn.* **2**, 259–285 (2008).
- 742 25. Smith, T. *et al.* An epidemiological model of the incidence of acute illness in *Plasmodium*
743 *falciparum* malaria. *Am. J. Trop. Med. Hyg.* **75**, 56–62 (2006).
- 744 26. Ross, A., Killeen, G. & Smith, T. Relationships between host infectivity to mosquitoes and asexual
745 parasite density in *Plasmodium falciparum*. *Am. J. Trop. Med. Hyg.* **75**, 32–37 (2006).
- 746 27. Reiker, T., Chitnis, N. & Smith, T. Modelling reactive case detection strategies for interrupting
747 transmission of *Plasmodium falciparum* malaria. *Malar. J.* **18**, 259 (2019).
- 748 28. Cameron, E. *et al.* Defining the relationship between infection prevalence and clinical incidence of
749 *Plasmodium falciparum* malaria. *Nat. Commun.* **6**, 8170 (2015).
- 750 29. Bâ, E.-H. *et al.* Implementation, coverage and equity of large-scale door-to-door delivery of
751 Seasonal Malaria Chemoprevention (SMC) to children under 10 in Senegal. *Sci. Rep.* **8**, 1–15 (2018).
- 752 30. Ekström, A. M. *et al.* INDEPTH Network: contributing to the data revolution. *Lancet Diabetes*
753 *Endocrinol.* **4**, 97 (2016).
- 754 31. Tediosi, F. *et al.* An approach to model the costs and effects of case management of *Plasmodium*
755 *falciparum* malaria in sub-saharan Africa. *Am. J. Trop. Med. Hyg.* **75**, 90–103 (2006).

- 756 32. WHO. Country profiles. <https://www.who.int/malaria/publications/country-profiles/en/> (2020).
- 757 33. Stein, M. Large Sample Properties of Simulations Using Latin Hypercube Sampling.
758 *Technometrics* **29**, 143–151 (1987).
- 759 34. OpenMalaria github. <https://github.com/SwissTPH/openmalaria/>.
- 760 35. White, M. T. *et al.* Dynamics of the antibody response to Plasmodium falciparum infection in
761 African children. *J. Infect. Dis.* **210**, 1115–1122 (2014).
- 762 36. Penny, M. A., Pemberton-Ross, P. & Smith, T. A. The time-course of protection of the RTS,S
763 vaccine against malaria infections and clinical disease. *Malar. J.* **14**, 437 (2015).
- 764 37. Griffin, J. T. *et al.* Protective Efficacy of Intermittent Preventive Treatment of Malaria in Infants
765 (IPTi) Using Sulfadoxine-Pyrimethamine and Parasite Resistance. *PLOS ONE* **5**, e12618 (2010).
- 766 38. Aponte, J. J. *et al.* Efficacy and safety of intermittent preventive treatment with sulfadoxine-
767 pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials.
768 *The Lancet* **374**, 1533–1542 (2009).
- 769 39. Rasmussen, C. E. Gaussian Processes in Machine Learning. in *Advanced Lectures on Machine*
770 *Learning: ML Summer Schools 2003, Canberra, Australia, February 2 - 14, 2003, Tübingen, Germany,*
771 *August 4 - 16, 2003, Revised Lectures* (eds. Bousquet, O., von Luxburg, U. & Rätsch, G.) 63–71 (Springer
772 Berlin Heidelberg, 2004). doi:10.1007/978-3-540-28650-9_4.
- 773 40. Kock, M. de *et al.* Population Pharmacokinetic Properties of Sulfadoxine and Pyrimethamine: a
774 Pooled Analysis To Inform Optimal Dosing in African Children with Uncomplicated Malaria. *Antimicrob.*
775 *Agents Chemother.* **62**, (2018).
- 776 41. Dahal, P. *et al.* Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated
777 Plasmodium falciparum malaria: pitfalls and challenges. *Malar. J.* **16**, 430–430 (2017).
- 778 42. Binois, M. & Gramacy, R. B. hetGP: Heteroskedastic Gaussian Process Modeling and Design
779 under Replication. *R package version* (2017).
- 780 43. Sobol', I. M. Global sensitivity indices for nonlinear mathematical models and their Monte Carlo
781 estimates. *Math. Comput. Simul.* **55**, 271–280 (2001).
- 782 44. Pitt, C. *et al.* Large-scale delivery of seasonal malaria chemoprevention to children under 10 in
783 Senegal: an economic analysis. *Health Policy Plan.* **32**, 1256–1266 (2017).
- 784 45. Gilmartin, C. & Collins, D. *The Costs of Seasonal Malaria Chemoprevention (SMC) in the Sahel*
785 *Sub-Region of Africa: A Multi-Country Cost Analysis of the ACCESS-SMC project.* (2016).
- 786 46. Flannery, E. L. *et al.* Assessing drug efficacy against Plasmodium falciparum liver stages in vivo.
787 *JCI Insight* **3**,.
- 788 47. NCT03707041. Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge
789 Model. <https://clinicaltrials.gov/ct2/show/record/NCT03707041> (2019).

- 790 48. Sulyok, M. *et al.* DSM265 for *Plasmodium falciparum* chemoprophylaxis: a randomised, double
791 blinded, phase 1 trial with controlled human malaria infection. *Lancet Infect. Dis.* **17**, 636–644 (2017).
- 792 49. Cissé, B. *et al.* Seasonal intermittent preventive treatment with artesunate and sulfadoxine-
793 pyrimethamine for prevention of malaria in Senegalese children: a randomised, placebo-controlled, double-
794 blind trial. *Lancet Lond. Engl.* **367**, 659–667 (2006).
- 795 50. Rogerson, S. J. *et al.* Identifying and combating the impacts of COVID-19 on malaria. *BMC Med.*
796 **18**, 239 (2020).
- 797 51. Borrmann, S., Peto, T., Snow, R. W., Gutteridge, W. & White, N. J. Revisiting the design of phase
798 III clinical trials of antimalarial drugs for uncomplicated *Plasmodium falciparum* malaria. *PLoS Med.* **5**,
799 e227–e227 (2008).
- 800 52. Kamath, A. V. Translational pharmacokinetics and pharmacodynamics of monoclonal antibodies.
801 *Drug Discov. Today Technol.* **21–22**, 75–83 (2016).
- 802 53. Julien, J.-P. & Wardemann, H. Antibodies against *Plasmodium falciparum* malaria at the molecular
803 level. *Nat. Rev. Immunol.* **19**, 761–775 (2019).
- 804 54. Kontermann, R. E. Strategies to extend plasma half-lives of recombinant antibodies. *BioDrugs*
805 *Clin. Immunother. Biopharm. Gene Ther.* **23**, 93–109 (2009).
- 806 55. Robbie, G. J. *et al.* A Novel Investigational Fc-Modified Humanized Monoclonal Antibody,
807 Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults. *Antimicrob. Agents Chemother.* **57**,
808 6147–6153 (2013).
- 809 56. Yu, X.-Q. *et al.* Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational,
810 Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy
811 Adults. *Antimicrob. Agents Chemother.* **61**, (2017).
- 812 57. Chughlay, M. F. *et al.* First-in-human clinical trial to assess the safety, tolerability and
813 pharmacokinetics of P218, a novel candidate for malaria chemoprotection. *Br. J. Clin. Pharmacol.* **86**,
814 1113–1124 (2020).
- 815 58. Penny, M. A. *et al.* Distribution of malaria exposure in endemic countries in Africa considering
816 country levels of effective treatment. *Malar. J.* **14**, 384 (2015).
- 817 59. Diouf, I. *et al.* Détermination des paramètres du paludisme au Sénégal à partir de données
818 météorologiques de stations et de réanalyses. *XXVIIIe Colloque de l'Association Internationale de*
819 *Climatologie, Liège 2015* (2015).
- 820 60. Traore, M. M. *et al.* Large-scale field trial of attractive toxic sugar baits (ATSB) for the control of
821 malaria vector mosquitoes in Mali, West Africa. *Malar. J.* **19**, 72 (2020).

822

823

824

Supplementary material for

825

Model informed target product profiles of long acting injectables for use as

826

seasonal malaria prevention

827

828

829 **Authors:**

830 Lydia Burgert^{1,2}, Theresa Reiker^{1,2}, Monica Golumbeanu^{1,2}, Jörg J. Möhrle^{1,2,3}, Melissa A. Penny*^{1,2}

831 ¹ Swiss Tropical and Public Health Institute, Basel, Switzerland

832 ² University of Basel, Basel, Switzerland

833 ³ Medicines for Malaria Venture, Geneva, Switzerland

834 *Corresponding author: melissa.penny@unibas.ch

835

836 **Table of Contents**

837 **1. General Open Malaria specification and intervention set-up 31**

838 **2. Non-inferiority analysis..... 34**

839 **3. Additional analysis results Error! Bookmark not defined.**

840 **4. Additional analysis results in the clinical trial setting 35**

841 **5. Additional analysis results in the implementation setting 36**


842 **6. Parameterization of SMC-SP+AQ to clinical trial data..... 43**

843

844

845


1. General OpenMalaria specification and intervention set-up



846 **Figure S 1: Prevalence - incidence relationship in the simulated Open Malaria settings.** The
 847 relationship between prevalence and incidence is displayed in the two simulated seasonal settings
 848 (Senegal/short season and Mali/long season) and health system access settings (low and high access) (Table
 849 1) in absence of any interventions. The clinical incidence defined as the events per person per year in the
 850 target age-group (0.25-5 years of age) is shown for the corresponding mean prevalence over one year in the
 851 intervention age group ($PfPR_{0.25-5y}$) and in children between 2-10 years ($PfPR_{2-10y}$). The dotted horizontal
 852 lines mark the incidence settings, simulated for all downstream analyses and can be found in Table S1.


853 **Table S 1: Simulated prevalence – incidence settings.** The force of transmission was defined by the
 854 entomological inoculation rate (EIR: mean number of infectious bites per person per year (pppy)). Across
 855 different transmission settings defined by health system access, EIR levels and transmission seasonality,
 856 corresponding simulated malaria prevalence (PfPR) and clinical incidence per person per year in the
 857 intervention age group is displayed for different age groups: 2 to 10 year olds ($PfPR_{2-10y}$) and 0.25 to 5 years
 858 old ($PfPR_{0.25-5y}$ and cases per person per year_{0.25-5y}).

HS Access	EIR [infectious bites pppy]	Short transmission season			Long transmission season		
		PfPR _{2-10y} [%]	PfPR _{0.25-5y} [%]	Cases per person per year _{0.25-5y}	PfPR _{2-10y} [%]	PfPR _{0.25-5y} [%]	Cases per person per year _{0.25-5y}
high	5	6	5	0.49	6	5	0.42
	9	13	11	0.95	13	10	1
	20	23	19	1.52	25	20	1.6
	47	37	28	2.04	39	30	2.2
	150	60	45	2.83	62	46	2.9
low	3	11	8	0.45	11	8	0.41
	4	19	13	0.72	17	13	0.71
	8	34	26	1.3	35	26	1.4
	28	59	48	2.3	62	50	2.4
	150	86	73	3.2	87	75	3.3




859

860 **Figure S 2: Modelled malaria transmission pattern and simulated prevalence defining seasonality**
 861 **settings.** The seasonality in malaria transmission is defined through the proportional EIR (solid line) in
 862 relation to the yearly EIR (input into the simulator). Here shown for a yearly EIR of 100 infectious bites
 863 per person per year. The dotted line represents the resulting scaled yearly prevalence profile. The arrows
 864 illustrate the administration of the preventative interventions of SMC-SP+AQ (green) and LAI (blue) in the
 865 two seasonal settings. Following WHO recommendations¹, SMC-SP+AQ was implemented monthly with
 866 the first dose administered before the peak and the second dose with the peak in malaria transmission.



867

868 **Figure S 3: Simulated protective efficacy decay shapes of long acting injectables (LAI) and seasonal**
 869 **malaria chemoprevention (SMC) over one transmission season.** The LAI decay shapes were chosen
 870 such that they represent the three possible development streams of mAb (sigmoid decay), drug based
 871 (exponential decay), or vaccine like (bi-phasic) LAIs (blue solid line). Here, we illustrated a LAI protective
 872 efficacy half-life of 120 days and initial protective efficacy of 100 %. SMC – SP+AQ was parameterised
 873 as specified below and administered up to four times over the transmission season (green solid line). The
 874 parameterisation of the interventions is further specified in Table 1.



875

876 **Figure S 4: Exemplary illustration of incidence and survival estimates of sigmoidal LAIs and SMC-**
 877 **SP+AQ in implementation stages over one implementation year.** Plots are shown in (a, c) low initial
 878 clinical incidence settings (initial cases per person per year_{0.25-5y} = 0.71) and (b, d) high initial clinical
 879 incidence settings (initial cases per person per year_{0.25-5y} = 3.3) in long malaria transmission settings with
 880 low access to health care ($E_{14}=0.1$). The sigmoidal LAIs exhibit an initial protective efficacy over 95 % and
 881 protective efficacy half-life of 112 days. SMC-SP+AQ and LAIs were implemented at high deployment
 882 coverage (>90%, solid lines) and low deployment coverage (<50%, dashed lines). In low initial incidence
 883 settings (a, c) SMC-SP+AQ (green) is administered four times per season (Aug-Nov) with clinical
 884 incidence notably decreasing after each administration (a, b) compared to control settings with no
 885 implemented interventions (black). In contrast, the sigmoidal LAIs are only administered once at the
 886 beginning of the transmission season. With progressing season, the protective efficacy decays, resulting in
 887 an increase of clinical cases (a, b) and decrease in survival estimates (c, d) after LAI administration. In low
 888 clinical incidence settings, sigmoidal LAIs and SMC-SP+AQ are comparably effective at both coverage
 889 levels (c). In contrast, the survival estimates in high initial clinical incidence settings (d) reveal that
 890 sigmoidal LAIs at both coverage levels and SMC-SP+AQ at low coverage levels are all equally unable to
 891 prevent malaria cases. Shown here are the mean predictions over 5 stochastic *OpenMalaria* simulations.

892

893 **2. Non-inferiority analysis**

894
895 Survival analysis was performed using a Kaplan-Meier approach as specified in ², with the K-M estimate
896 $\hat{S}(t)$ derived via number of new clinical cases c_i at each time step t_i

897
898
$$\hat{S}(t) = \prod_{i:t_i \leq t} \mathbf{1} - \frac{c_i}{N_{int}}, \quad \text{Eq. S6}$$

899 with the standard error \widehat{SE} calculated using the Greenwood formula

900
$$\widehat{SE}(t) = [\hat{S}(t)] \sqrt{\prod_{i:t_i \leq t} \frac{c_i}{N_{int}(N_{int}-c_i)}}. \quad \text{Eq. S7}$$

901 Non-inferiority analysis was conducted based on the survival statistics as described in ². The survival
902 estimate (hazard ratio) for the standard of care SMC $\hat{S}_{SMC}(t)$ considering the desired margin of non-
903 inferiority Δ defines the upper limit for non-inferiority γ :

904
$$\gamma = \frac{\ln(\hat{S}_{SMC} - \Delta)}{\ln(\hat{S}_{SMC})} \quad \text{Eq. S8}$$

905 The difference δ between the survival estimates of the standard of care SMC $\hat{S}_{SMC}(t)$ and new treatment
906 (LAI) \hat{S}_{LAI} , is calculated on the log-log- scale and is equivalent to the logarithm of the ratio of cumulative
907 hazards in the two groups

908
$$\delta = \ln(-\ln(\hat{S}_{SMC})) - \ln(-\ln(\hat{S}_{LAI})) = \ln \frac{\hat{H}_{SMC}(t)}{\hat{H}_{LAI}(t)} \quad \text{Eq. S9}$$

909 and its variance is calculated as follows:

911
$$Var(\delta) = \left\{ \frac{1}{\ln(\hat{S}_{SMC})} \right\}^2 \frac{1}{\hat{S}_{SMC}^2} Var(\hat{S}_{SMC}) + \left\{ \frac{1}{\ln(\hat{S}_{LAI})} \right\}^2 \frac{1}{\hat{S}_{LAI}^2} Var(\hat{S}_{LAI}) \quad \text{Eq. S10}$$

912 The confidence interval of the hazard ratio δ is given by $exp^{\delta [95\% CI: \delta \pm 1.96 \times se(\delta)]}$. Non-inferiority is
913 established if the upper limit of the derived 95% confidence interval, CI_{high} , of the hazard ratios δ between
914 SMC and LAI lies below the upper limit for non-inferiority γ .

915

916 **3. Emulator performance**

917 **Table S 2: Emulator performance for the investigated outcomes.** The emulator performance was
 918 assessed by calculating the Pearson correlation coefficient (PCC) and the mean absolute error (MAE)
 919 between true and predicted values on a 20% holdout set for each investigated setting.

Outcome	PCC (median [min, max])	MAE (median [min, max])
upper limit for non-inferiority γ	0.9924 [0.8072, 0.9972]	0.0015 [0.0002, 0.0280]
upper limit of the hazard ratio	0.9945 [0.9472, 0.9978]	0.0229 [0.0094, 0.0791]
Clinical incidence SMC-SP+AQ, (cases per person per year _{0.25-5y, SMC})	0.9964 [0.9787, 0.9986]	0.0142 [0.0060, 0.0428]
Clinical incidence LAIs, (cases per person per year _{0.25-5y, LAI})	0.9947 [0.9562, 0.9985]	0.0136 [0.0055, 0.0488]

920

921 **4. Additional analysis results in the clinical trial setting**


922 **Table S 3: Incidence reduction achieved through implementation of SMC-SP+AQ in a clinical trial**
 923 **setting.** The incidence reduction was calculated in the clinical trial setting over three months in the short
 924 season setting and four months in the long season setting. Resistance to SMC-SP+AQ is implemented as a
 925 reduction in protective efficacy half-life from 32 days to 20 days.

	EIR [infectious bites pppy]	Short malaria transmission season	long malaria transmission season
		inc _{red} [%]	inc _{red} [%]
No resistance to SMC- SP+AQ	5	90	87
	9	90	87
	20	90	88
	47	89	87
	150	88	86
Resistance to SMC-SP+AQ	3	79	76
	4	76	75
	8	76	72
	28	73	72
	150	73	71

926


927
928

5. Additional analysis results in the implementation setting



929


930 **Figure S 5: Estimated impact of LAI properties and operational factors on the level of clinical**
 931 **incidence reduction.** Results are shown for the implementation stage in a setting with low access to care
 932 ($E_{14}=0.1$) and short (Senegal-like) malaria transmission season, for (a-c) *exponential LAIs*, (d-f) *bi-phasic*
 933 *LAIs*, and (g-i) *sigmoidal LAIs*. Changes in clinical incidence measured as cases per person per year_{0,25-5y}
 934 with increasing tool properties or deployment coverage across the parameter space are shown for for (a, d,
 935 g) half-life (30-150 d), (b, e, h) initial efficacy (80-100%) and (c, f, i) coverage (40-100%). The lines
 936 represent the mean and the 95%-confidence bands (shaded area) capture the distribution of incidence
 937 reduction across all sampled values. Increasing color intensity represents increasing initial cases per person
 938 per year_{0,25-5y}. These results hold true for high access to healthcare settings. The conversion of initial cases
 939 per person per year_{0,25-5y} to prevalence can be found in Table S1.



940

941 **Figure S 6: Estimated impact of LAI properties and operational factors on the level of clinical**
 942 **incidence reduction.** Results are shown for the implementation stage in a setting with low access to care
 943 ($E_{14}=0.1$) and long (Mali-like) malaria transmission season, for (a-c) *exponential LAIs*, (d-f) *bi-phasic LAIs*,
 944 and (g-i) *sigmoidal LAIs*. Changes in clinical incidence measured as cases per person per year_{0.25-5y} with
 945 increasing tool properties or deployment coverage across the parameter space are shown for for (a, d, g)
 946 half-life (30-150 d), (b, e, h) initial efficacy (80-100%) and (c, f, i) coverage (40 -100 %). The lines
 947 represent the mean and the 95%- confidence bands (shaded area) capture the distribution of incidence
 948 reduction across all sampled values. Increasing color intensity represents increasing initial clinical
 949 incidence (cases per person per year_{0.25-5y}). These results hold true for high access to healthcare settings.
 950 The conversion of initial cases per person per year_{0.25-5y} to prevalence can be found in Table S1.


951



952


953 **Figure S 7: Incidence reduction achieved through implementation of SMC-SP+AQ over varying**
 954 **deployment coverage.** The results are shown for low (a, b) and high (c, d) access to health care and short
 955 (a, c) and long (b, d) malaria seasons. The colors indicate different initial clinical incidence before
 956 introduction of SMC-SP+AQ (initial cases per person per year_{0,25-5y}). The incidence reduction_{0,25-5y} was
 957 calculated in the implementation scenario after one year of implementation. The grey lines indicate the
 958 additional incidence reduction (0,25-5y) achieved by increasing SMC-SP+AQ coverage from 62% to 100 %.

959



960


961 **Figure S 8: Estimated minimal LAI coverage required during *implementation stages* to achieve non-**
 962 **inferiority in a given setting.** Heatmap of the estimated minimal coverage (colour) of LAIs at which non-
 963 inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60% in each of the 3 or 4 rounds) is
 964 achieved for different combinations of protective efficacy decay, initial protective efficacy and protective
 965 efficacy half-life. The results are displayed for intervention scenarios with a low access to care ($E_{14}=0.1$) in
 966 the two seasonal settings. In the grey area, non-inferiority could not be established for any combination of
 967 tool properties. The LAI coverage could not be optimized for high transmission settings (initial cases per
 968 person per year_{0.25-5y}=3.2) because they fail to sufficiently protect the targeted population from clinical
 969 malaria even at full deployment coverage. Therefore, optimisation of the LAI deployment coverage could
 970 not be conducted (Fig. S4).



971

972 **Figure S9: Estimated minimal LAI coverage required during implementation stages to achieve non-**
 973 **inferiority in a given setting.** Heatmap of the estimated minimal coverage (colour) of LAIs at which non-
 974 inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60% in each of the 3 or 4 rounds) is
 975 achieved for different combinations of protective efficacy decay, initial protective efficacy and protective
 976 efficacy half-life. The results are displayed for intervention scenarios with a high access to care ($E_{14}=0.5$)
 977 in the two seasonal settings. In the grey area, non-inferiority could not be established for any combination
 978 of tool properties. The LAI coverage could not be optimized for high transmission settings (initial cases per
 979 person per year_{0.25-5y}=2.9) because they fail to sufficiently protect the targeted population from clinical

980 malaria even at full deployment coverage. Therefore, optimisation of the LAI deployment coverage could
981 not be conducted (Fig. S4).



982

983 **Figure S10: Estimated minimal LAI coverage required during implementation stages to achieve non-**
 984 **inferiority in a given setting and predicted gains in cases averted of subsequent exponential LAI**
 985 **coverage increments.** ((a) Heatmap of the estimated minimal coverage (colour) of sigmoidal LAIs at which
 986 non-inferiority to SMC-SP+AQ (assuming a fixed SMC coverage of 60%) is achieved for different
 987 combinations of exponential LAI efficacy and half-life. The results are displayed for intervention scenarios
 988 with an underlying disease burden of 1.4 cases per person per year_{0.25-5y}, long malaria transmission season
 989 and low access to treatment ($E_{14}=0.1$). In the grey area, non-inferiority could not be established for any
 990 coverage. For the tool characteristics within the light-blue frames, non-inferiority could be reached with a
 991 LAI coverage under the reference SMC-SP+AQ coverage of 60%. The coloured dots represent four
 992 illustrative LAI profiles of (b) 150 days half-life and 100% initial efficacy (yellow), (c) 100 days half-life
 993 and 90% initial efficacy (light green), (d) 90 days half-life and 80% initial efficacy (blue), and (e) 70 days
 994 half-life and 70% initial efficacy (dark green, e). (b-e). Corresponding predicted relative differences in
 995 cases per person per year_{0.25-5y} (Eq. 5) are calculated for the illustrative LAIs (coloured dots) in (a) in the
 996 last implementation year (5 years after LAI introduction) over all LAI coverages as compared to SMC-
 997 SP+AQ at 60% coverage (vertical dotted line). The predicted positive increase in relative difference in
 998 yearly clinical cases (above the dotted horizontal line) means more clinical cases are averted with LAIs
 999 than with SMC-SP+AQ. It thus illustrates the benefit of increasing exponential LAI-coverage above the
 1000 minimal required coverage to achieve non-inferiority (shown by the grey coloured area). In the light-blue
 1001 area in (b), a LAI coverage lower than the SMC-SP+AQ coverage is sufficient to establish non-inferiority.

1002

1003

1004 **6. Parameterization of SMC-SP+AQ to clinical trial data**

1005 Seasonal malaria chemoprotection (SMC) was implemented as sulfadoxine–pyrimethamine+amodiquine
 1006 (SP-AQ) treatment and calibrated to a randomized non-inferiority trial of dihydroartemisinin-piperaquine
 1007 with SP-AQ, conducted between August 2009 and January 2010 in rural western Burkina Faso Zongo et
 1008 al.(2015)³. Decay of protective efficacy of SPAQ in the field over time was extracted from Fig.3 in Zongo
 1009 et al.(2015)³ and used to parameterized the decay functions as specified in *OpenMalaria* using a least
 1010 squares approach combined with a Gaussian-Process optimization. The trial described in Zongo et
 1011 al.(2015)¹ was rebuilt in OM settings listed in Table S4.

1012 **Table S 4: Inputs into OpenMalaria to check adequate parameterization of SMC with SP-AQ.**

	Parameter	Value	Ref.
Vector specification	Mosquito species [% of total abundance]	<i>An. funestus</i> : 42% indoor, 31% outdoor <i>An. gambiae</i> : 14% indoor, 13% outdoor	4
	Total EIR	154	4
	Seasonality in malaria transmission [mo. EIR]	<i>An. funestus</i> : Aug Sep Oct Nov 23 16 0 3.1 <i>An. gambiae</i> : Aug Sep Oct Nov 40 50 16 6.4	4
	Health System Access to treatment	2003 2006 Effective coverage E_{14} [%] 50 50 OM 5 day probability E_5 [%] 24.12 24.12	5, 6
	Malaria treatment	First line: Artemeter-Lumefantrine Treatment failure/Severe malaria: Quinine	5
Vector Interventions	Coverage of ITNs	2006-2008: 14%	5
	ITN coverage during trial	27%	3
Seasonal Malaria Chemoprevention	Timing of interventions	SMC: 15. Aug, 15. Sep, & 15.Oct 2009 Follow-up: 1. Sep, 1.Oct & 1. Nov 2009	3
	Protective efficacy of SP+AQ	$E(t) = E0 e^{-\left(\frac{t}{L}\right)^k \log(2)}$ Parameter ranges for LHS sampling: Half-life L : [20, 60] days Shape parameter k : [1, 10] Initial efficacy $E0$: [0.7, 1]	3


1013

1014 We used Latin-Hypercube sampling (LHS) to generate 5000 samples of the decay function parameters for
 1015 protective efficacy (L , k , $E0$) within the parameter bounds given in Table S4. The trial was simulated with
 1016 these parameters and five seeds per parameter-set for the intervention and control cohort. The protective
 1017 efficacy E of SMC - SP+AQ in the simulated trial compared to the simulated controls (without intervention)
 1018 was extracted by comparing cases per person (cpp) between the intervention group (cpp_{int}) and control
 1019 group (cpp_{cont}) over the trial period as follows:

1020
$$E = 1 - \frac{cpp_{int}}{cpp_{cont}} \quad \text{Equ. S11}$$

1021 The residual sum of squares (RSS) between the protective efficacy given in Zongo et al.(2015)³ and
 1022 protective efficacy from OM simulations was extracted and a Gaussian process (GP) regression was trained
 1023 to predict the RSS between trial results and OM simulation with the parameters of the protective efficacy
 1024 decay.

1025 The true over predicted RSS of the hold-out of 1000 data points is shown in Fig. S11.



1026

1027 **Figure S 11: True over predicted RSS of the GP.**

1028 The GP was then optimized via non-linear optimization using the augmented Lagrange method (function
 1029 gosolnp, R-package Rsolnp). We optimized the mean predicted error +/- one or two standard deviation of
 1030 the residual sum of squares (RSS) between the protective efficacy in Zongo et al.(2015)³ and the OM
 1031 simulation output. The parameters of the decay function returned by the optimization process were re-
 1032 simulated with OM and the RSS extracted (*RSS OM*). The OM simulation resulting in the least RSS was
 1033 then selected for further analysis.

1034 **Table S 5: Results of the GP optimization.** The results of the optimization *RSS optim* is compared with
 1035 the *predicted (pred.)* RSS by the GP and the RSS extracted from OM simulations (median of 5 seeds)
 1036 conducted with the respective parameters (*RSS OM*). The solver was restarted 20 times and the number of
 1037 random parameters generated for every restart was set to n.sim=500.

	kdecay	Half-life	Initial efficacy	RSS optim	RSS pred	RSS OM
Min. RSS before optimisation	6.35	32.5	0.97	-	0.0842	0.0601
mean	5.40	31.3	1.0	0.0538	0.0538	0.0556
Mean +sd	5.29	31.5	1.0	0.0882	0.0542	0.0583
Mean - sd	5.58	31.0	1.0	0.0186	0.0545	0.0538
Mean + 2*sd	5.28	31.5	1.0	0.0895	0.0541	0.0556
Mean - 2*sd	5.62	31.1	1.0	0.0172	0.0544	0.0739


1038

1039 The OM implementation of the best parameter set for the intervention cohort is able to well capture the
 1040 protective efficacy described in ³. The protective efficacy (Figure S12), cumulative hazard (Fig. S13) and
 1041 prevalence over time (Fig. S14) provide more insight into the trial results and comparison with OM outputs.

1042 **Table S 6: Comparison of trial results of Zongo et al., 2015 ³ and model outputs using the model**
 1043 **specification in Table S4 with the best parameter set.** The compared time-points correspond to the time-
 1044 points compared in ³. The difference in prevalence of parasitemia in December 2009 in the untreated cohort
 1045 are caused by ongoing but decreasing transmission in December (see Figure S3) and unclear definition of
 1046 data time-point in ³.

	Zongo et al., 2015	OM [min, max]
Prevalence of parasitemia [%] in August 2009, intervention cohort	45	45 [44, 48]
Prevalence of parasitemia [%] in September 2009, untreated cohort	61	60 [57, 65]
Cumulative hazard for fever with any parasitemia intervention cohort	0.22	0.14 [0.13, 0.15]
Cumulative hazard for fever with any parasitemia intervention cohort	0.92	1.01 [0.93, 1.12]
Prevalence of parasitemia [%] in November 2009, intervention cohort	12	19 [18, 20]
Prevalence of parasitemia [%] in December 2009, untreated cohort	36	46 [39, 48]


1047



1048


1049 **Figure S 12: Decay of protective efficacy of SMC-SP+AQ over time.** Population protective efficacy over
 1050 time in the trial setting. The purple line represents the protective efficacy as extracted from Zongo et
 1051 al.(2015) ³. The new parameterization after optimization and uncertainty are shown in blue and red.

1052



1053

1054 **Figure S 13: Cumulative hazard of malaria in children who received SMC with SP-AQ (blue)**
1055 **compared to controls (black).** The cumulative hazard over time was calculated using the Nelson-Aalen
1056 estimator. See Fig. 2 in Zongo et al.(2015)³ for comparison.



1057

1058 **Figure S 14: Prevalence of malaria in children who received SMC with SP-AQ (blue) compared to**
1059 **controls (black) over the trial.** The prevalence in the intervention cohort is decreasing with each SMC
1060 round every month and then slowly increasing again. At the same time, the prevalence in the control group
1061 is increasing with the ongoing malaria transmission season. After the last SMC round, there is an increase
1062 of prevalence caused by still ongoing transmission. Simultaneously, the transmission intensity is already
1063 decreasing as can be seen in the control cohort prevalence.

- 1064 1. WHO. WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for
1065 Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in
1066 Africa. (World Health Organization, 2012).
- 1067 2. Dahal, P. et al. Statistical methods to derive efficacy estimates of anti-malarials for uncomplicated
1068 Plasmodium falciparum malaria: pitfalls and challenges. *Malar. J.* **16**, 430–430 (2017).
- 1069 3. Zongo, I. et al. Randomized Noninferiority Trial of Dihydroartemisinin-Piperaquine Compared
1070 with Sulfadoxine-Pyrimethamine plus Amodiaquine for Seasonal Malaria Chemoprevention in Burkina
1071 Faso. *Antimicrob. Agents Chemother.* **59**, 4387–4396 (2015).
- 1072 4. Dabire, K. R. et al. *Anopheles funestus* (Diptera: Culicidae) in a humid savannah area of western
1073 Burkina Faso: bionomics, insecticide resistance status, and role in malaria transmission. *J Med Entomol* **44**,
1074 990–7 (2007).
- 1075 5. WHO. World malaria report 2008. (World Health Organization, 2008).
- 1076 6. Penny, M. A. et al. Distribution of malaria exposure in endemic countries in Africa considering
1077 country levels of effective treatment. *Malar. J.* **14**, 384 (2015).
- 1078
- 1079